奥美拉唑治疗反流性咽喉炎不同疗程的疗效评价

齐智伟; 陆鸿略; 张洁; 张淑君

doi:10.13201/j.issn.1001-1781.2018.09.012

奥美拉唑治疗反流性咽喉炎不同疗程的疗效评价

- 承德医学院附属医院耳鼻咽喉科(河北承德, 067000)

详细信息

通讯作者: 张淑君, E-mail:cdcd2007@163.com

中图分类号: R767.1

收稿日期: 2018-01-19

Effect of different course of omeprazole in the treatment of laryngopharyngeal reflux

- Department of Otorhinolaryngology, Affiliated Hospital of Chengde Medical College, Chengde, 067000, China

More Information

Corresponding author: ZHANG Shujun, E-mail: cdcd2007@163.com

Received Date: 19 January 2018

摘要

摘要: 目的: 比较不同疗程奥美拉唑治疗反流性咽喉炎的疗效及安全性。方法: 选取2015-03-2017-01期间收治的160例咽喉反流患者(诊断性治疗8周确诊),随机分为A组、B组、C组、D组,每组40例。每组患者均口服奥美拉唑肠溶胶囊20 mg,Bid,疗程分别为1、2、3、4个月。比较4组患者治疗前、疗程结束时及疗程结束后1个月、2个月的反流症状指数量表(RSI)、反流体征指数量表(RFS)评分、24 h食管pH值测定及胃蛋白酶检测结果,并评定疗效和不良反应。结果: 随着疗程增加,患者的RSI评分、RFS 评分、24 h食管内pH值<4.0占总时间的百分率、胃蛋白酶阳性率均渐降低,治疗前后差异有统计学意义;治疗后B组和A组、C组和B组差异有统计学意义,D组和C组比较差异无统计学意义;疗程结束后至随访2个月, A组、B组3次RSI、RFS评分渐升高,24 h食管内pH值<4.0占总时间的百分率增加,胃蛋白酶阳性率升高(均P>0.05),C组、D组3次RSI评分、RFS评分、24 h食管内pH<4.0占总时间的百分率、胃蛋白酶阳性率均差异无统计学意义。随着疗程增加,治疗的有效率增加,分别为67.5%、80.0%、90.0%、95.0%,差异有统计学意义(P<0.05),但不良反应并没有增加(P>0.05)。结论: 奥美拉唑治疗咽喉反流安全有效,疗程5个月患者的症状体征明显好转,并且病情相对稳定、复发率较低。
- 咽喉反流 /
- 奥美拉唑 /
- 疗程
Abstract: Objective: To compare the efficacy and safety of omeprazole in the treatment of laryngopharyngeal reflux.Method: One hundred and sixty patients with laryngopharyngeal reflux in our hospital from March 2015 to January 2017 (diagnosis treatment for 8 weeks) were selected and randomly divided into group A, B, C, D, with 40 cases in each group. Each group of patients were treated with omeprazole enteric-coated capsules (20mg, Bid) for 1, 2, 3 and 4 months, respectively. The reflux symptom index(RSI), reflux finding score(RFS) score, and 24h intraesophageal pH-metry, pepsin detection were compared between the four groups before treatment, at the end of treatment, at 1 month and 2 months after treatment. The efficacy and side effects were evaluated.Result: With the increase of treatment course, patient's RSI and RFS score, 24h pH-metry <4.0 percentage, pepsin positive rate decreased gradually, and there was a significant difference between before and after treatment. After treatment, there was a statistical significance in group B and group A, group C and group B. There was no significant difference between group D and group C. After the end of treatment and up to 2 months of follow-up, the RSI and RFS scores gradually increased and 24h Ph-metry <4.0 percentage, pepsin positive rate increased in group A and B,and those were not significantly different in group C and group D. With the increase of treatment duration, the effective rate of treatment increased, which was 67.5%, 80.0%, 90.0% and 95.0%, respectively. The difference was statistically significant, but the adverse effects did not increase (P>0.05).Conclusion: Omeprazole is safe and effective in the treatment of laryngopharyngeal reflux. The symptoms and signs of the patients are obviously improved during the 5 months of the course, and the condition is relatively stable and the recurrence rate is low.
- laryngopharyngeal reflux /
- omeprazole /
- course

HTML全文

参考文献(15)

[1]	LEE J S, LEE Y C, KIM S W, et al.Changes in the quality of life of patients with laryngopharyngeal reflux after treatment[J].J Voice, 2014, 28:487-491.
[2]	王晶, 赵宇, 任建君, 等.咽喉反流与慢性鼻-鼻窦炎[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (20):1663-1666.
[3]	吴彦桥, 梁芳芳.咽喉反流性鼻炎的临床初步研究[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (3):200-202.
[4]	BELAFSKY P C, POSTMA G N, KOUFMAN J A.Validity and reliability of the reflux symptom index (RSI)[J].J Voice, 2002, 16:274-277.
[5]	BELAFSKY P C, POSTMA G N, KOUFMAN J A.The validity and reliability of the reflux finding score (RFS)[J].Laryngoscope, 2001, 111:1313-1317.
[6]	WILLIAMS R B H, SZCZESNIAK M M, MACLEAN J C, et al.Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis[J].Am J Gastroenterol, 2004, 99:777-780.
[7]	胡全福, 谢景华.咽喉反流患者鼻腔分泌物中胃蛋白酶的检测及意义[J].中国实验诊断学, 2016, 20 (1):64-66.
[8]	ELSERAG H B, LEE P, BUCHNER A, et al.Lansoprazole treatment of patients with chronic idiopathic laryngitis:aplacebo controlled trial[J].Am J Gastroenterol, 2001, 96:979-983.
[9]	李卡凡, 钟艳萍, 蔡小剑, 等.奥美拉唑治疗反流性咽喉炎的效果[J].广东医学, 2014, 35 (24):3893-3895.
[10]	罗花南, 马思敬, 高滢, 等.质子泵抑制剂治疗咽喉反流患者声嘶症状的疗效观察[J].临床耳鼻咽喉头颈外科杂志, 2015, 29 (11):997-1001.
[11]	赵荣, 刘海兵.咽喉反流性疾病58例诊疗体会[J].临床耳鼻咽喉头颈外科杂志, 2011, 25 (15):690-691.
[12]	马一菡, 罗斌阳, 王一平, 等.长期应用质子泵抑制剂的不良反应[J].临床合理用药杂志, 2014, 32 (2):141-144.
[13]	王小蕾, 王蔚虹.长期服用质子泵抑制剂需要关注的临床问题[J].临床药物治疗杂志, 2009, 7 (1):6-11.
[14]	蒋绚, 张庆文, 张振宇, 等.长期应用质子泵抑制剂的风险观察[J].中华医学杂志, 2014, 94 (4):284-288.
[15]	王秀, 陈伟, 王秋萍.胃蛋白酶检测在咽喉反流疾病诊断中的应用[J].临床耳鼻咽喉头颈外科杂志, 2017, 31 (9):728-731.